Bole Tian

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Xing Huang · 2 shared papers, 2024 · strength 0.57
   • Paper LncRNA VASH1 antisense RNA 1/miR-199a-5p/Programmed Cell Death 4 Axis Regulate Proliferation, Apoptosis, and Cell Cycle… DOI 10.1166/jbn.2024.3834↗
   • Paper Flubendazole presents anti-tumor effects by promoting cell cycle arrest and inhibiting the invadopodia in pancreatic ca… DOI 10.21203/rs.3.rs-4570726/v1↗
2. Wei Liu · 1 shared paper, 2024 · strength 0.31
   • Paper LncRNA VASH1 antisense RNA 1/miR-199a-5p/Programmed Cell Death 4 Axis Regulate Proliferation, Apoptosis, and Cell Cycle… DOI 10.1166/jbn.2024.3834↗
3. Xiao Tan · 1 shared paper, 2024 · strength 0.31
   • Paper LncRNA VASH1 antisense RNA 1/miR-199a-5p/Programmed Cell Death 4 Axis Regulate Proliferation, Apoptosis, and Cell Cycle… DOI 10.1166/jbn.2024.3834↗
4. Yi Zhang · 2 shared papers, 2021–2025 · strength 0.30
   • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
   • Paper Mitochondrial-Associated Protein LRPPRC is Related With Poor Prognosis Potentially and Exerts as an Oncogene Via Mainta… DOI 10.3389/fgene.2021.817672↗
5. Yi Zhang · 1 shared paper, 2023 · strength 0.26
   • Paper Section the tumor and divest the arterial sheath in a patient with locally advanced pancreatic cancer. DOI 10.1016/j.asjsur.2022.07.125↗
6. Dan Cao · 1 shared paper, 2023 · strength 0.26
   • Paper Section the tumor and divest the arterial sheath in a patient with locally advanced pancreatic cancer. DOI 10.1016/j.asjsur.2022.07.125↗
7. Yi Jin · 1 shared paper, 2023 · strength 0.26
   • Paper Section the tumor and divest the arterial sheath in a patient with locally advanced pancreatic cancer. DOI 10.1016/j.asjsur.2022.07.125↗
8. Pengcheng Zhao · 1 shared paper, 2024 · strength 0.26
   • Paper Flubendazole presents anti-tumor effects by promoting cell cycle arrest and inhibiting the invadopodia in pancreatic ca… DOI 10.21203/rs.3.rs-4570726/v1↗
9. Kang Xue · 1 shared paper, 2024 · strength 0.26
   • Paper Flubendazole presents anti-tumor effects by promoting cell cycle arrest and inhibiting the invadopodia in pancreatic ca… DOI 10.21203/rs.3.rs-4570726/v1↗
10. Zihe Wang · 1 shared paper, 2024 · strength 0.26
    • Paper Flubendazole presents anti-tumor effects by promoting cell cycle arrest and inhibiting the invadopodia in pancreatic ca… DOI 10.21203/rs.3.rs-4570726/v1↗
11. Xing Huang · 1 shared paper, 2021 · strength 0.19
    • Paper Role of the microbiome in systemic therapy for pancreatic ductal adenocarcinoma (Review). DOI 10.3892/ijo.2021.5281↗
12. Li Mao · 1 shared paper, 2021 · strength 0.19
    • Paper Role of the microbiome in systemic therapy for pancreatic ductal adenocarcinoma (Review). DOI 10.3892/ijo.2021.5281↗
13. Chengjian Zhao · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
14. Xiaoying Li · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
15. Zixing Huang · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
16. Chen Chang · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
17. Junjie Xiong · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
18. Yi Cheng · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
19. Ke Cheng · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
20. Huanji Xu · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
21. Dan Cao · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
22. Xiaorui Zhu · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
23. Rui Wang · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
24. Qingqing Leng · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
25. Wanting Hou · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.